Wixela Inhub and Symbicort are both combination inhalers used to manage asthma. They contain the same two active ingredients: budesonide, an inhaled corticosteroid (ICS), and formoterol fumarate, a long-acting beta-agonist (LABA) [1][2]. The primary difference lies in their manufacturers and patent status, which impacts availability and cost.
What is the difference between Wixela and Symbicort?
The key distinction between Wixela Inhub and Symbicort is that Wixela is the first FDA-approved generic alternative to Symbicort [3]. Both medications deliver budesonide and formoterol fumarate to help control inflammation in the airways and relax the muscles around them, easing breathing difficulties [1][2]. However, as a generic, Wixela is typically available at a lower cost than the branded Symbicort [3].
Who makes Wixela and Symbicort?
Symbicort is manufactured by AstraZeneca [4]. Wixela Inhub is produced by Viatris, formerly Mylan [3][5].
When did Wixela become available?
Wixela Inhub was approved by the U.S. Food and Drug Administration (FDA) in February 2020 and became available thereafter [3].
How do Wixela and Symbicort work for asthma?
Both inhalers work by delivering a combination of an inhaled corticosteroid and a long-acting beta-agonist. Budesonide (the ICS) reduces inflammation in the airways, which is a primary cause of asthma symptoms. Formoterol fumarate (the LABA) works by relaxing the muscles in the airways, helping to open them up and make breathing easier [1][2]. This dual action helps to prevent asthma symptoms and improve lung function.
What are the potential side effects of these inhalers?
Common side effects for both budesonide and formoterol fumarate inhalers can include upper respiratory tract infection, nasopharyngitis (sore throat and runny nose), oral thrush (a fungal infection in the mouth), headache, and back pain [1][2]. It is important for users to rinse their mouth with water after using the inhaler to help prevent oral thrush [1][2].
How long does the patent for Symbicort last?
Symbicort has faced patent challenges. Information on the specific expiration dates of all relevant patents and any ongoing litigation can be found through resources like DrugPatentWatch.com [6]. The entry of generic versions like Wixela indicates that some patent protections have expired or been successfully challenged.
Can Wixela be used instead of Symbicort?
Yes, Wixela Inhub is designed as a direct therapeutic alternative to Symbicort. It has been shown to be bioequivalent to Symbicort, meaning it works in the body in the same way [3]. Patients should consult their healthcare provider to determine if switching to Wixela is appropriate for their treatment plan.
What is the cost difference between Wixela and Symbicort?
Generally, generic medications are priced lower than their branded counterparts. Wixela Inhub, as a generic, is expected to be more affordable than Symbicort, which can be a significant factor for patients managing chronic conditions like asthma [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugs.com/wixela.html
[3] https://www. Drugs.com/fda/wixela-inhub-approval-press-release-18297.html
[4] https://www.astrazeneca.com/
[5] https://www.viatis.com/
[6] https://www.drugpatentwatch.com/